AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Nautilus Biotechnology In... (NAUT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.72

0.01 (0.58%)

At close: Feb 18, 2025, 3:59 PM

1.71

-0.29%

After-hours: Feb 18, 2025, 04:00 PM EST

undefined% (undefined)

Bid	1.67
Market Cap	215.34M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.56
PE Ratio (ttm)	-3.06
Forward PE	n/a
Analyst	Sell

Ask	1.88
Volume	59,438
Avg. Volume (20D)	134,961
Open	1.74
Previous Close	1.71
Day's Range	1.66 - 1.75
52-Week Range	1.56 - 3.09
Beta	undefined

About NAUT

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington....

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 7, 2020

Employees 161

Stock Exchange NASDAQ

Ticker Symbol NAUT

Website https://www.nautilus.bio

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for NAUT stock is "Sell." The 12-month stock price forecast is $3, which is an increase of 74.93% from the latest price.

Buy 33.33%

Hold 33.33%

Sell 33.33%

Stock Forecasts

Why Price Moved

7 months ago

+2.7%

Nautilus Biotechnology shares are trading higher a... Unlock content with Pro Subscription

9 months ago

-1.17%

Nautilus Biotechnology shares are trading higher after the company reported better-than-expected Q1 EPS results.

News

3 months ago · seekingalpha.com

Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder and Chief Executiv...